CN117500796B - 亚磺酰亚胺类化合物及其应用 - Google Patents

亚磺酰亚胺类化合物及其应用

Info

Publication number
CN117500796B
CN117500796B CN202280043560.8A CN202280043560A CN117500796B CN 117500796 B CN117500796 B CN 117500796B CN 202280043560 A CN202280043560 A CN 202280043560A CN 117500796 B CN117500796 B CN 117500796B
Authority
CN
China
Prior art keywords
compound
mol
mmol
pharmaceutically acceptable
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280043560.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN117500796A (zh
Inventor
钱文远
杨纯道
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yousen Jianheng Biomedical Shanghai Co ltd
Original Assignee
Yousen Jianheng Biomedical Technology Zhongshan Co ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yousen Jianheng Biomedical Technology Zhongshan Co ltd, Medshine Discovery Inc filed Critical Yousen Jianheng Biomedical Technology Zhongshan Co ltd
Publication of CN117500796A publication Critical patent/CN117500796A/zh
Application granted granted Critical
Publication of CN117500796B publication Critical patent/CN117500796B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280043560.8A 2021-06-22 2022-06-22 亚磺酰亚胺类化合物及其应用 Active CN117500796B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021106944971 2021-06-22
CN202110694497 2021-06-22
CN202210002094 2022-01-04
CN2022100020940 2022-01-04
CN2022106657539 2022-06-13
CN202210665753 2022-06-13
PCT/CN2022/100435 WO2022268119A1 (zh) 2021-06-22 2022-06-22 亚磺酰亚胺类化合物及其应用

Publications (2)

Publication Number Publication Date
CN117500796A CN117500796A (zh) 2024-02-02
CN117500796B true CN117500796B (zh) 2026-03-27

Family

ID=84545187

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280043560.8A Active CN117500796B (zh) 2021-06-22 2022-06-22 亚磺酰亚胺类化合物及其应用

Country Status (12)

Country Link
US (1) US20240376093A1 (enExample)
EP (1) EP4361138A4 (enExample)
JP (1) JP2024526156A (enExample)
KR (1) KR20240024906A (enExample)
CN (1) CN117500796B (enExample)
AU (1) AU2022298616A1 (enExample)
BR (1) BR112023026964A2 (enExample)
CA (1) CA3223641A1 (enExample)
IL (1) IL309572A (enExample)
MX (1) MX2023015440A (enExample)
TW (1) TWI825800B (enExample)
WO (1) WO2022268119A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239699A (zh) * 2022-12-22 2025-07-01 祐森健恒生物医药（上海）有限公司 一种吡啶多取代化合物的盐型、晶型及其制备方法
WO2025186427A1 (en) * 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022105771A1 (zh) * 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) * 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
CN111936486B (zh) * 2018-03-22 2023-09-22 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
JP7631193B2 (ja) * 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
AU2019373203B2 (en) * 2018-10-30 2024-10-24 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
CN213366611U (zh) * 2018-11-05 2021-06-04 深圳市优行新能源有限公司 光伏组件
SG11202108162SA (en) * 2019-01-30 2021-08-30 Bristol Myers Squibb Co Amide-disubstituted pyridine or pyridazine compounds
AU2021254764A1 (en) * 2020-04-14 2022-11-03 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
KR20230004771A (ko) * 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022105771A1 (zh) * 2020-11-17 2022-05-27 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CN117500796A (zh) 2024-02-02
US20240376093A1 (en) 2024-11-14
BR112023026964A2 (pt) 2024-03-12
WO2022268119A1 (zh) 2022-12-29
EP4361138A4 (en) 2025-05-21
IL309572A (en) 2024-02-01
CA3223641A1 (en) 2022-12-29
TW202315869A (zh) 2023-04-16
KR20240024906A (ko) 2024-02-26
EP4361138A1 (en) 2024-05-01
AU2022298616A1 (en) 2024-01-18
MX2023015440A (es) 2024-04-29
TWI825800B (zh) 2023-12-11
JP2024526156A (ja) 2024-07-17

Similar Documents

Publication Publication Date Title
EP3555070B1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
US20170355712A1 (en) Amine-substituted aryl or heteroaryl compounds
JP7425724B2 (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
EP4206197B1 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
KR100389192B1 (ko) 축합 피리다진 유도체, 그것의 제조 방법 및 용도
CN112839655B (zh) 甲状腺激素受体β促效剂化合物
EP3519393B1 (en) Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
KR20240004495A (ko) 이소퀴놀론 화합물과 이의 용도
EP4055013B1 (en) Wdr5 inhibitors and modulators
EP4043450A1 (en) 2h-benzopyran derivatives as crac inhibitors
CN117500796B (zh) 亚磺酰亚胺类化合物及其应用
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN116234551A (zh) 一类1,7-萘啶类化合物及其应用
WO2021228248A1 (zh) 氮杂稠环酰胺类化合物及其用途
KR102833011B1 (ko) 푸로[3,4-b]피롤-함유 BTK 억제제
TW202136267A (zh) Ｂｒｕｔｏｎ酪胺酸激酶（ＢＴＫ）抑制劑
CN114644633B (zh) 杂环类jak抑制剂
EA049128B1 (ru) Сульфоксиминовое соединение и его применение
WO2025151602A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
HK40098892A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
CN119192203A (zh) 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
CN117777138A (zh) 作为泛素-特异性蛋白酶1抑制剂的含氮杂环化合及其制备方法和用途
BR122024013896A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
NZ795530A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40102573

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241225

Address after: 2nd Floor, Building 8, No. 88 Darwin Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant after: Yousen Jianheng biomedical (Shanghai) Co.,Ltd.

Country or region after: China

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

Country or region before: China

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 528451 Guangdong Province Zhongshan City Nanzhao Street Cuiheng New District Heqing Road No. 10 Zhongshan Life Science Park Building 11 6th Floor Room 2

Applicant after: Yousen Jianheng Biomedical Technology (Zhongshan) Co.,Ltd.

Address before: 2nd Floor, Building 8, No. 88 Darwin Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: Yousen Jianheng biomedical (Shanghai) Co.,Ltd.

Country or region before: China

GR01 Patent grant
GR01 Patent grant